Docoh
Loading...

KZIA Kazia Therapeutics Limited

News

From Benzinga Pro
A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
15 Nov 21
Earnings, News, Penny Stocks, Eurozone, Futures, Global, Pre-Market Outlook, Markets
Pre-open movers
Kazia Therapeutics Named John Friend, MD, as Chief Medical Officer
14 Nov 21
News, Penny Stocks, Management
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr.
Kazia Therapeutics Enrolls First Patient In PNOC Study In Childhood Brain Cancer
10 Nov 21
News, FDA
https://www.kaziatherapeutics.com/site/PDF/36882fd7-9d99-4ca5-ac45-2a6c0d143d5c/KaziaenrolsfirstpatienttoPNOCstudy
Kazia Therapeutics Sponsored Study Titled 'Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours' Posted To ClinicalTrials.gov; Study Is Recruiting
10 Nov 21
News, FDA
https://clinicaltrials.gov/ct2/show/NCT05114668
Kazia Therapeutics Announced it Enrolled First Patient to EVT801 Phase I Clinical Trial
4 Nov 21
News
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021. Key Points
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Maxim Group Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $18
14 Oct 21
News, Price Target, Initiation, Analyst Ratings
Maxim Group analyst Naureen Quibria initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $18.
Kazia Therapeutics To Present At LD Micro Main Event From Oct. 12-14
6 Oct 21
News, FDA, Events
Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held
Kazia Therapeutics Announced EVT801 Phase I Study Receives Full Regulatory Approval in France
2 Sep 21
News
Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to inform stakeholders that the planned phase I study for EVT801 has received full approval from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French regulatory agency.

Press releases

From Benzinga Pro
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
15 Nov 21
Small Cap, Press Releases
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical
Proactive news headlines including Chase Mining Corporation, Orthocell Ltd, Eclipse Metals and SenSen Networks
15 Nov 21
M&A, News, Contracts, Management, Press Releases
Sydney, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Chase Mining Corporation Ltd
PNOC Study in Childhood Brain Cancer Enrols First Patient
11 Nov 21
Small Cap, Press Releases
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in
Proactive news headlines including Blue Star Helium, Yandal Resources, Alto Metals and Alice Queen Ltd
11 Nov 21
M&A, News, Contracts, Management, Press Releases
Sydney, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Blue Star Helium Ltd ((ASX:BNL,
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
4 Nov 21
Press Releases
SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial
Proactive news headlines including Marvel Gold, Perseus Mining, Duke Exploration and Lake Resources
29 Oct 21
M&A, News, Contracts, Management, Press Releases
Sydney, Oct. 30, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Marvel Gold Ltd (ASX:MVL) has
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
14 Oct 21
News, Press Releases
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed
Kazia Therapeutics to Present at LD Micro Main Event
6 Oct 21
Small Cap, Press Releases
SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
10 Sep 21
Press Releases
SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC
Proactive news headlines including Great Boulder Resources, Pan Asia Metals, Chimeric Therapeutics and archTIS
2 Sep 21
M&A, News, Contracts, Management, Press Releases
Sydney, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Great Boulder Resources Ltd (ASX:GBR)